A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy

Trial Profile

A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 15 May 2015 According to a Teva Pharmaceuticals industries media release, data from this trial will be presented at the 2015 Annual International Meeting of the American Thoracic Society.
    • 21 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top